NCT00195299已完成不适用
An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 20 人开始时间: 2005年4月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with newly diagnosed, advanced stage, head and neck squamous cell carcinoma of the oral cavity, oral pharynx, hypopharynx or larynx.
- •Subjects willing to undergo tumor biopsies.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Age >/= 18 years.
排除标准
- •Subjects receiving anticoagulation therapy.
- •Presence of unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia.
- •Prior cancer therapy (chemotherapy, hormonal therapy, radiotherapy, immunotherapy) or investigational agent for their head and neck cancer.
研究者
相似试验
已完成
1 期
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid TumorsAdenocarcinomaNeoplasmsNCT00106353Pfizer71
Unknown
2 期
Temsirolimus in Recurrent Primary Central Nervous System (CNS) LymphomaRecurrent or Refractory Primary CNS LymphomaNCT00942747Charite University, Berlin, Germany37
已完成
2 期
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaNCT00494091Pfizer82
已完成
2 期
Efficacy Study of Temsirolimus to Treat Head and Neck CancerHead and Neck Squamous Cell CarcinomaNCT01172769Hannover Medical School42
Unknown
2 期
Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)Chronic Limb IschemiaNCT02908035Mercator MedSystems, Inc.100